Analysis of the effectiveness of cinnamon in the reduction of sugar and fat levels of adults with type 2 Diabetes

Analysis of the effectiveness of cinnamon (Cinnamomum verum) in the reduction of glycemic and lipidic levels of adults with type 2 Diabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

REBEC

Registry ID

RBR-2kkb6d

Enrollment

Unknown

Registered

2019-10-02

Start date

2019-08-01

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

Participants will be divided into Experimental Group (GE) and Control Group (CG). In GE, participants with type 2 diabetes, HbA1c between 6.5 and 8.0%, will receive doctor-prescribed oral antidiabetic

Drug

B01.650.940.800.575.912.250.595.400.149.124

D26.660

G07.203.300.456

Eligibility

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Volunteers of both genders; aged between 18 and 80 years; diagnosis of type 2 diabetes confirmed for at least five years; taking oral antidiabetics; with HbA1c values between 6.5 and 8.0%; preserved cognitive functions.

Exclusion criteria

Exclusion criteria: Volunteers with cinnamon allergy; Patients who use another herbal medicine for diabetes treatment; Patients using cinnamon for diabetes treatment; Patients diagnosed with alcoholic liver disease, cirrhosis or abnormal basal liver function; Patients on insulin therapy; Women breastfeeding, pregnant or on contraceptives; Patients with heart, liver or respiratory failure; Patients with bleeding disorders and who are taking coumarin derivatives.

Design outcomes

Primary

Measure	Time frame
Reduction in glycemic levels;For HbA1c, it is expected to find decreased values, measured by a blood test after the intervention period, and presented as percentage values. We will look at what implications these variables will have on the management and control of the glycemic profile of patients with type 2 diabetes.;For fasting glucose, it is expected to find decreased values, measured by a blood test after the intervention period, and presented in total values of mg / dL. We will look at what implications these variables will have on the management and control of the glycemic profile of patients with type 2 diabetes.	—

Measure

Time frame

Reduction in glycemic levels;For HbA1c, it is expected to find decreased values, measured by a blood test after the intervention period, and presented as percentage values. We will look at what implications these variables will have on the management and control of the glycemic profile of patients with type 2 diabetes.;For fasting glucose, it is expected to find decreased values, measured by a blood test after the intervention period, and presented in total values of mg / dL. We will look at what implications these variables will have on the management and control of the glycemic profile of patients with type 2 diabetes.

—

Secondary

Measure	Time frame
The thickness of adiposity, anthropometrical values, and lipid marker.;For adiposity levels and anthropometric values, characterized by body mass index, central adiposity index, waist circumference, neck circumference, waist-hip ratio, waist-thigh ratio, waist-height ratio, it is expected to find decreased values. , measured by an inelastic tape, digital scale, and ratio calculations after the intervention period, and presented in total values or through cutoff points. It is hoped that the values have decreased after the intervention and that the implications of excess fat can be minimized.;Lipids characterized by LDL-cholesterol, triglycerides and total cholesterol, it is expected to find a decrease of at least 10% of values, measured by a blood test after the intervention, and presented in mg / dL. For the HDL marker, they are expected to have increased values, given the protection against cardiovascular complications. The values are expected to be positively altered and, through the estimated analysis, patients can decrease diabetes-related risks and achieve diabetes metabolic control.	—

Measure

Time frame

The thickness of adiposity, anthropometrical values, and lipid marker.;For adiposity levels and anthropometric values, characterized by body mass index, central adiposity index, waist circumference, neck circumference, waist-hip ratio, waist-thigh ratio, waist-height ratio, it is expected to find decreased values. , measured by an inelastic tape, digital scale, and ratio calculations after the intervention period, and presented in total values or through cutoff points. It is hoped that the values have decreased after the intervention and that the implications of excess fat can be minimized.;Lipids characterized by LDL-cholesterol, triglycerides and total cholesterol, it is expected to find a decrease of at least 10% of values, measured by a blood test after the intervention, and presented in mg / dL. For the HDL marker, they are expected to have increased values, given the protection against cardiovascular complications. The values are expected to be positively altered and, through the estimated analysis, patients can decrease diabetes-related risks and achieve diabetes metabolic control.

—

Countries

Brazil

Contacts

Public ContactMarta ;Marta Coelho Damasceno;Coelho Damasceno

Universidade Federal do Ceará;Universidade Federal do Ceará

profamartamcdamasceno@gmail.com;profamartamcdamasceno@gmail.com+5585996225253;+5585996225253

Outcome results

None listed

Source: REBEC (via WHO ICTRP)